Evidence map›Paper›PMID 41064541›Full record

ArticleCase reports in gastroenterology

Case Report: Secukinumab (Interleukin-17 Inhibitor) and Ulcerative Colitis Flare - the Double-Edged Sword.

Joaquin Ongay, Ivanna Candel, Alain Bitton, Waqqas Afif, Talat Bessissow, Peter L Lakatos

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Joaquin OngayDivision of Gastroenterology and Hepatology, McGill University Health Center, Montreal, QC, Canada.
Ivanna CandelDivision of Gastroenterology and Hepatology, McGill University Health Center, Montreal, QC, Canada.
Alain BittonDivision of Gastroenterology and Hepatology, McGill University Health Center, Montreal, QC, Canada.
Waqqas AfifDivision of Gastroenterology and Hepatology, McGill University Health Center, Montreal, QC, Canada.
Talat BessissowDivision of Gastroenterology and Hepatology, McGill University Health Center, Montreal, QC, Canada.
Peter L LakatosDivision of Gastroenterology and Hepatology, McGill University Health Center, Montreal, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Secukinumab is an interleukin (IL)-17A inhibitor approved for psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Its use has been reported to be associated with inflammatory bowel disease (IBD) flare and new onset. Case Presentation: We report a case of a 56-year-old woman with longstanding ulcerative colitis (UC) in remission, who developed a severe UC flare after initiating secukinumab for refractory PsA. She presented with extensive ulcerations, systemic inflammation needing hospitalization, and change of treatment to risankizumab. Conclusion: This case highlights the emerging evidence of IL-17A blockade in IBD, potentially leading to adverse events, and adds to the growing body of evidence regarding the management of such complications with novel therapeutic approaches in severe cases. Physicians should be aware of this possibility when using IL-17A blockade in patients with pre-existing IBD.

Indexed as

Case reportInflammatory bowel diseaseRisankizumabSecukinumabUlcerative colitis

Identifiers

PMID41064541
PMCPMC12503613

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.